Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of small molecule polypeptide kp-1 in preparing medicine for treating chronic kidney disease

A technology for small molecule peptides and chronic kidney disease, which is used in drug combinations, medical preparations containing active ingredients, and pharmaceutical formulations.

Active Publication Date: 2020-03-06
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still no effective drugs to delay the progression of CKD clinically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of small molecule polypeptide kp-1 in preparing medicine for treating chronic kidney disease
  • Application of small molecule polypeptide kp-1 in preparing medicine for treating chronic kidney disease
  • Application of small molecule polypeptide kp-1 in preparing medicine for treating chronic kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Screening of KP-1 Small Molecule Peptides

[0025] 1. Experimental materials:

[0026] Cells: Rat kidney fibroblasts (NRK-49F).

[0027] Culture medium: DMEM / F12 (1:1) culture medium containing 10% FBS.

[0028] Culture conditions: 37 o C contains 5% CO 2 incubator.

[0029] Small molecule peptide library: 18 peptide sequences were designed by computer, each with an average length of 30 amino acids, which were artificially synthesized by Nanjing GenScript Biotechnology Co., Ltd. to build a small molecule peptide library.

[0030] 2. Experimental treatment:

[0031] (I) The cultured rat kidney fibroblasts were mixed with 1.5×10 6 They were planted in 6-well cell culture plates, cultured for 1 day, starved for 24 hours, and given 18 different small molecule peptides (10 µg / ml) 1 hour in advance. Then stimulated with TGF-β recombinant protein (2ng / ml), collected the protein 48 hours later, and carried out Western blot experiments to screen the peptides th...

Embodiment 2

[0039] Example 2: Distribution of FITC-labeled KP-1 in various organs in UUO mice

[0040] 1. Experimental animals: C57 mice, male, weighing 20-22g, SPF grade.

[0041] The animals were first weighed and numbered, and 2 healthy mice weighing 20-22 g were selected and divided into UUO and UUO+KP-1.

[0042] 2. Experimental grouping

[0043] 1) UUO mice: at room temperature, anesthetize the mouse with 1% pentobarbital sodium at 5ml / kg body weight, select the left abdomen 2-3cm as the incision; after local disinfection, cut the skin, subcutaneous, muscle layer and For the peritoneum, after finding the left ureter, ligate the upper 1 / 3 of the ureter and suture layer by layer. After local disinfection, check the marks and place them in corresponding mouse cages.

[0044] 2) UUO+KP-1 mice: anesthetize and disinfect as above. The skin, subcutaneous layer, muscle layer and peritoneum were cut layer by layer. After finding the left ureter, the upper 1 / 3 segment of the ureter was li...

Embodiment 3

[0049] Example 3: Inhibitory effect of small molecule polypeptide KP-1 on renal fibrosis in mouse UUO model

[0050] 1. Experimental animals: BALB / C mice, male, weighing 20-22g, SPF grade.

[0051] The animals were first weighed and numbered, and 12 healthy mice weighing 20-22 g were selected and randomly divided into 3 groups, 6 in each group. Including sham operation group, model control group and medication group.

[0052] 2. Experimental grouping

[0053] 1) Sham operation group: After mice were anesthetized with 1% sodium pentobarbital at 5 ml / kg body weight at room temperature, the incision was 2-3 cm from the left abdomen; after local disinfection, the skin, subcutaneous layer, and muscular layer were cut layer by layer And peritoneum, found the left ureter, then sutured layer by layer. After local disinfection, check the marks and place them in corresponding mouse cages.

[0054] 2) Model control group: anesthetized and disinfected as above. The skin, subcutaneous...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel application of a micro-molecule polypeptide KP-1, and in particular to an application of the micro-molecule polypeptide KP-1 in preparing a medicine for treating chronic kidney diseases (CKD). The invention provides the application of the KP-1 in treating the CKD; and the KP-1 is obvious in curative effect and is free from obvious toxic and side effects. Therefore,the KP-1 provided by the invention can be used for preparing a pharmaceutical preparation for treating the CKD.

Description

technical field [0001] The present invention relates to the use of a unique small molecule polypeptide in the treatment of chronic kidney disease (CKD), in particular to the use of KP-1 polypeptide in the preparation of medicines for treating CKD. Background technique [0002] Chronic kidney disease (CKD) eventually progresses to end-stage renal failure (ESRD), and patients rely on "renal replacement therapy" for life to maintain their lives. In the past few decades, along with the aging of the human society, the prevalence of CKD has been increasing year by year (Nat Rev Nephrol, 2011, 7: 684-696). Some data indicate that CKD is becoming a "public health problem", which seriously endangers human health and consumes a lot of health resources. However, currently there are no drugs that can effectively delay the progression of CKD clinically. Aiming at the pathogenesis of CKD, finding drugs that can effectively inhibit or delay the progress of CKD is undoubtedly an urgent ta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/16A61P13/12
CPCA61K38/16
Inventor 周丽丽
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com